The Canadian amyotrophic lateral sclerosis (ALS) community is calling for the country’s government to invest CA$50 million (about $36 million) over the next five years to support the Canadian Collaboration to Cure ALS. Advocates, including people with ALS, caregivers, clinicians, and researchers, gathered at Parliament Hill on Oct. 2…
News
In a new study by a team of U.S. scientists, a group of inflammatory immune cells was found to mistakenly target the C9ORF72 protein in nerve cells in people with amyotrophic lateral sclerosis (ALS) — demonstrating that ALS may be an autoimmune disease. The findings, by researchers at the…
For years, researchers have been chasing a so-called silver bullet compound that could effectively treat anyone with amyotrophic lateral sclerosis (ALS). Hande Ozdinler, an associate professor of neurology at Northwestern University, thinks that this approach should be reassessed and a different, more nuanced view of ALS treatment should…
FGF21, a hormone that helps cells regulate energy use and respond to stress, may protect muscles and nerve cells from damage related to amyotrophic lateral sclerosis (ALS), slowing disease progression. A study found ALS patients had significantly higher levels of FGF21 in their blood and muscles than healthy controls,…
Researchers identified three forms, or biotypes, of amyotrophic lateral sclerosis (ALS), each with distinct mechanisms that could suggest pathways for biologically specific treatment. A machine learning model was able to classify people with ALS into these three groups using demographic and disease-related information. “The machine learning model we developed,…
Immune checkpoint proteins — proteins that help regulate immune response — were elevated on T-cells and in the blood of people with amyotrophic lateral sclerosis (ALS), a small study found, suggesting they may play a role in how the disease develops. The increases were associated with more severe…
The ALS Network is honoring actor Eric Dane as its Advocate of the Year, granting the former TV doctor the annual award in recognition of his efforts and commitment to raising awareness and support for people living with amyotrophic lateral sclerosis (ALS). The award will be presented at…
Patient enrollment is complete in a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast), an investigational oral therapy developed by Medicinova to treat amyotrophic lateral sclerosis (ALS). The COMBAT-ALS (NCT04057898) trial is testing whether MN-166 can safely slow ALS progression in 234 adults with ALS, ages 18 to…
Coya Therapeutics has launched a Phase 2 clinical trial of COYA 302 — an experimental therapy combining the signaling molecule IL-2 with CTLA4-Ig, also known as abatacept — to evaluate whether its use can slow disease progression in adults with amyotrophic lateral sclerosis (ALS) over a six-month period.
In adults with amyotrophic lateral sclerosis (ALS) who have slower disease progression, the stem cell therapy Neuronata-R (lenzumestrocel) — conditionally approved in South Korea for treating ALS — was found to help preserve daily function and breathing capacity, while also reducing signs of nerve damage and inflammation. That’s according to…
Recent Posts
- New funding backs commercial readiness efforts for ALS therapy
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients